89
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Zoledronic acid for cancer therapy-induced and postmenopausal bone loss

, MD PhD
Pages 1013-1028 | Published online: 01 Apr 2008
 

Abstract

Background: Cancer therapy-induced bone loss (CTIBL) and bone loss in postmenopausal (PMW) increase fracture risk. Objective: To review the efficacy and safety of zoledronic acid (ZA) for prevention and treatment of CTIBL and postmenopausal bone loss. Methods: Using PubMed, a search of the English language literature (January 1950 to November 2007) was performed to identify articles evaluating ZA in CTIBL patients without bone metastases and for postmenopausal bone loss; articles were reviewed and evaluated. Results/conclusion: Intermittent administration of ZA increases BMD, decreases bone turnover markers, and is well tolerated in both cancer patients without bone metastases and osteopenic/osteoporotic PMW. In osteopenic/osteoporotic PMW, ZA also decreases fracture rates and prevents second fractures. The optimal regimens in these populations are unknown.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.